FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
1. FDA approved updated REMS labeling for TVTX's Filspari. 2. Liver function monitoring frequency reduced to every three months. 3. Embryo-fetal toxicity monitoring requirement removed based on safety data. 4. Supplemental FDA application for Filspari in FSGS under review. 5. Filspari could be the first approved medicine for FSGS.